The impact of personalised therapies on respiratory medicine

Area of Science:

• Precision medicine
• Genetics and personalized therapy
• Respiratory medicine

Background:

• Stratified medicine maximizes treatment efficacy by identifying patient subgroups likely to respond.
• This approach, pioneered in oncology, is increasingly applied to other diseases like asthma and cystic fibrosis (CF).
• CF therapies are being developed to target specific functional classes of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Purpose of the Study:

• To evaluate the efficacy of ivacaftor, a potentiator of CFTR protein, in patients with Class III mutations.
• To assess the impact of ivacaftor on clinically important outcomes in CF patients with the G551D mutation.

Main Methods:

• Clinical studies involving patients with the G551D mutation, a common Class III CFTR mutation.
• Administration of ivacaftor to potentiate the function of the defective CFTR protein.
• Measurement of spirometry, exacerbations, sweat chloride levels, and symptom scores.

Main Results:

• Ivacaftor demonstrated significant improvements in spirometry and reduced exacerbations in G551D mutation patients.
• A significant reduction in sweat chloride levels confirmed the functional effect on CFTR protein.
• Patients reported greatly improved symptom scores, indicating a transformational treatment effect.

Conclusions:

• Ivacaftor is a transformational, stratified therapy for CF patients with the G551D mutation.
• Targeting specific CFTR mutation classes represents a promising strategy for developing new CF therapies.
• This approach is likely to lead to novel drugs or combinations to correct the basic defect in CF.